About MDxHealth

MDxHealth is a molecular diagnostics company that develops and commercializes innovative tests for cancer assessment and the personalized treatments of patients. Utilizing our proprietary, patented DNA methylation platform and biomarkers, we help address the large and growing unmet medical need by offering tests that aid in the improvement of cancer diagnostics, prognosis and treatment.

About UrNCollect (Available ex-US)

UrNCollect is a user-friendly device that enables a hygienic and standardized collection of the first 16 mL of the urine stream and reduces lab errors by automating preservative mixing without additional handling or traditional pipetting. 

About ConfirmMDx for Prostate Cancer

ConfirmMDx is an epigenetic assay to help urologists distinguish patients who have a true-negative biopsy from those at risk for occult cancer.  The test is able to detect an epigenetic field effect associated with the cancerization process at the DNA level. This field effect around a cancer lesion can be present despite having a normal appearance under the microscope.

The test helps urologists:

  • Rule out prostate cancer-free men from undergoing unnecessary repeat biopsies
  • Rule in high-risk patients who may require repeat biopsies and potential treatment

MDxHealth Receives 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award

MDxHealth's CEO Jan Groen Ph.D. Bolero Interview

MDxHealth & Andros Clinic


MDxHealth's Nijmegen Laboratory

Check out 

How a simple urine test can now help doctors spot signs of prostate cancer with 98 per cent accuracy